MNG18
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.404
- KRAS_SIGNALING_DN+0.311
- CHOLESTEROL_HOMEOSTASIS+0.223
- APICAL_SURFACE+0.216
- INTERFERON_ALPHA_RESPONSE+0.213
- MYOGENESIS+0.210
- APOPTOSIS+0.205
- UV_RESPONSE_DN+0.192
- INFLAMMATORY_RESPONSE+0.190
- INTERFERON_GAMMA_RESPONSE+0.151
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.544
- E2F_TARGETS-0.458
- G2M_CHECKPOINT-0.442
- MYC_TARGETS_V1-0.419
- MYC_TARGETS_V2-0.337
- ADIPOGENESIS-0.312
- MITOTIC_SPINDLE-0.295
- DNA_REPAIR-0.292
- UNFOLDED_PROTEIN_RESPONSE-0.273
- GLYCOLYSIS-0.269
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1358826 | GTEX | — | 0.840 |
| 2 | a802b49c.736d.427c.bcca.8375c4171284 | — | cohortA1 | 0.839 |
| 3 | TCGA-56-8623-01A-11R-A28V-07 | — | cohortA1 | 0.839 |
| 4 | sclcMAD11162_S44.txt | — | cohortA1 | 0.827 |
| 5 | SRR1457221 | GTEX | — | 0.827 |
| 6 | MNG809 | — | — | 0.826 |
| 7 | SRR1470902 | GTEX | — | 0.825 |
| 8 | SRR603752 | GTEX | — | 0.815 |
| 9 | TCGA-55-8513-01A-11R-2403-07 | — | cohortA1 | 0.814 |
| 10 | BS_NPQJ20KX | pilocytic astrocytoma | — | 0.814 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.404 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.311 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.223 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.216 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.213 | Inavolisib | — uncovered |
| MYOGENESIS | 0.210 | Inavolisib | — uncovered |
| APOPTOSIS | 0.205 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.192 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.190 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.151 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.129 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.128 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.097 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.096 | Inavolisib | — uncovered |
| HYPOXIA | 0.096 | Idelalisib | — uncovered |
| COAGULATION | 0.090 | Binimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.081 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.063 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.061 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.050 | Inavolisib | — uncovered |